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Direct sequencing of genes is effective method in detec-
tion of mutations associated with high predisposition to
breast cancer, however is also expensive and time con-
suming. Therefore, we developed a rapid genetic test for
detection of high risk of breast cancer in Polish popula-
tion. We selected 15 mutations located in four genes
associated with high predisposition to breast cancer in
Poland: BRCA1 - 5 mutations (Górski et al. IJC 2004)
BRCA2 – 5 mutations (Górski et al. IJC 2004, Serrano
Fernandez et al. BCRT 2009), CHEK2 – 4m u t a t i o n s
(Cybulski et al. Clin Res. 2006, Cybulski et al. BCRT
2007, Cybulski et al.JMG 2009, Cybulski et al. Clin
Genet. 2009, Gronwald et al.BJC 2010) i ATM – 1
mutations (Bogdanowa et al. BCRT 2009).
For genotyping we used the Real-Time PCR technique
and custom-made Taqman assays. This test is rapid
(results of Taqman genotyping we are available within 2
hours), cheap, easy and sensitive in detection of muta-
tions in genes associated with high predisposition to
breast cancer.
In order to meet all sensitivity and quality standards
for such tests we are using positive, negative and
blinded control in each analysis. The specificity and
reproducibility of this test is assessed by repeated analy-
sis of 10% samples. All positive results are confirmed by
analysis of second sample from the same patient by
independent method eg. PCR-RFLP or sequencing.
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